Sonnet BioTherapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

Commitments and Contingencies (Details Narrative) € in Millions		1 Months Ended		3 Months Ended		6 Months Ended
	Apr. 30, 2023 USD ($)	Apr. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2023 EUR (€)	Jan. 31, 2019 USD ($)
Loss Contingencies [Line Items]
Payment to acquire in process research and development						$ 261,250	$ 285,627
Research and development expense				$ 3,816,644	$ 6,405,273	7,562,584	10,671,138
Discovery Collaboration Agreements [Member] \| XOMA [Member]
Loss Contingencies [Line Items]
Milestone payments				3,800,000		$ 3,800,000
Discovery Collaboration Agreements [Member] \| XOMA [Member] \| In Process Research and Development [Member]
Loss Contingencies [Line Items]
Annual license fee		$ 500,000
Cellca Agreement [Member]
Loss Contingencies [Line Items]
Description of milestone payments						The Company is obligated to make milestone payments to Cellca totaling up to $0.7 million upon the achievement of certain development and approval milestones if the Buy-Out Option is not exercised.
Cellca Agreement [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Milestone payments									$ 700,000
The Cellca Agreement [Member]
Loss Contingencies [Line Items]
Milestone payments				600,000		$ 600,000
The Cellca Agreement [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Payment for annual license fee obligation				600,000		600,000
The Cellca Agreement [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Payment for annual license fee obligation				100,000		100,000
The Cellca Agreement [Member] \| In Process Research and Development [Member]
Loss Contingencies [Line Items]
Commercial product license fee payment obligation		$ 100,000
The Brink Agreement [Member]
Loss Contingencies [Line Items]
Commercial product license fee payment obligation				100,000		100,000
Payment of annual license fee				12,000		12,000
The Brink Agreement [Member] \| In Process Research and Development [Member]
Loss Contingencies [Line Items]
Annual license fee				12,000	100,000	12,000	100,000
Commercial product license fee payment obligation				100,000		100,000
Invivo Gen Agreement [Member]
Loss Contingencies [Line Items]
Annual license fee				0		0
Payment for annual license fee obligation				100,000		100,000		€ 0.1
Invivo Gen Agreement [Member] \| In Process Research and Development [Member]
Loss Contingencies [Line Items]
Annual license fee					100,000		100,000
Proteo Nic Agreement [Member]
Loss Contingencies [Line Items]
Milestone payments				1,300,000		1,300,000		€ 1.2
Annual license fee				0	$ 0	0	0
Proteo Nic Agreement [Member] \| In Process Research and Development [Member]
Loss Contingencies [Line Items]
Annual license fee			$ 24,600
Navigo Agreement [Member] \| Navigo Proteins GmbH [Member] \| Technology Service [Member]
Loss Contingencies [Line Items]
Milestone payments				$ 1,000,000.0		1,000,000.0
Payment to acquire in process research and development							$ 100,000
Research and development expense						$ 100,000
Navigo Agreement [Member] \| Navigo Proteins GmbH [Member] \| Technology Service [Member] \| Subsequent Event [Member]
Loss Contingencies [Line Items]
Annual license fee	$ 200,000